Info Building Better Bones: PTH Analogs, HDAC Inhibitors, and Hormonal Synergies in Skeletal and Craniofacial Growth

[Archelaus]

PTH Analogs: Mechanism of Action​

PTH analogs are engineered to replicate the anabolic effects of endogenous PTH while minimizing undesirable catabolic effects. The two main FDA-approved analogs are:

---

1. Teriparatide (PTH 1-34)​

• Structure: Recombinant fragment containing the first 34 amino acids of PTH (the active binding region).
  • Binds to PTH1 receptors on osteoblasts, activating cAMP/PKA and Wnt/β-catenin pathways.
  • Stimulates osteoblast proliferation and differentiation, increasing bone mineral density (BMD).
• Half life: 1 hour (subcutaneous administration).

---

2. Abaloparatide (PTHrP Analog)​

• Structure: Synthetic analog of parathyroid hormone-related protein (PTHrP), sharing homology with PTH.
  • Selective binding to the RG conformation of PTH1R, favoring bone formation over resorption.
  • Shorter receptor activation time compared to teriparatide, reducing hypercalcemia risk.
• Half-life: 1.7 hours (subcutaneous administration).

---

Clinical Applications​

1. Osteoporosis Treatment​

• Indications:
  
  • Postmenopausal women and men at high fracture risk.
  • Patients unresponsive to bisphosphonates or with severe osteoporosis (T-score < -3.0).
  • Teriparatide increases lumbar spine BMD by 9–13% over 18 months.
  • Abaloparatide shows similar efficacy with a lower hypercalcemia risk.
• Duration: Limited to 24 months (lifetime) due to osteosarcoma risk (observed in rodent studies).

2. Hypoparathyroidism​

• PTH (1-84) (Natpara):
  
  • Full-length recombinant PTH for chronic hypoparathyroidism.
  • Restores calcium homeostasis, reducing reliance on high-dose calcium and vitamin D.
  • Discontinued in 2019 due to manufacturing issues but remains available in some regions.

---

Pharmacokinetics and Administration​

• Route: Subcutaneous injection (daily for teriparatide/abaloparatide).
• Absorption: Rapid, peak concentrations within 30–60 minutes.
• Metabolism: Cleared via renal and hepatic pathways.

---

Adverse Effects and Contraindications​

Common Side Effects​

• Hypercalcemia (more frequent with teriparatide).
• Orthostatic hypotension, dizziness.
• Injection site reactions.

Serious Risks​

• Osteosarcoma: Seen in preclinical studies (no confirmed human cases, but caution advised).
• Hypercalciuria and nephrolithiasis.

Contraindications​

• Paget's disease of bone.
• Prior radiation therapy to bone.
• Pediatric patients (open epiphyses).

---

Practical Application​

• Teriparatide: Administer once per day at 20 micrograms.
• Abaloparatide: Administer once per day at 80 micrograms.

---

HDACI Synergy with Anabolics and Growth Factors​

1. Anavar​

• Increases bone density and height velocity.

2. Trenbolone​

• Very high affinity for the androgen receptor; HDACI will be able to amplify these transcriptional effects and further upregulate AR.

3. Growth Factors + HDACI​

• IGF-1 LR3 / GH: HDACI increase IGF-1R sensitivity, synergizing with GH’s conversion into IGF-1 and other IGF-1 analogues.
• BMP-2/7: Accelerates osteogenesis in targeted areas (e.g., maxilla).

4. Mechanical Loading + HDACI​

• Orthodontics/Orthopedics: HDACI can enhance bone remodeling in response to functional appliances, palatal expanders.
• Manual mechanical force techniques: Remodeling response to applied mechanical force is amplified.

---

Risks​

1. Asymmetry Risk​

• Uneven HDACI + mechanical loading could lead to skewed growth (e.g., mandibular asymmetry).
• Important to apply force evenly and reassess symmetry of growth.

2. Overgrowth Concerns​

• Uncontrolled osteoblast activation might cause excessive bone thickening (e.g., prognathism).
• Not an issue if facial bones are underdeveloped in these areas, but relevant if the focus is on height and frame development, with craniofacial growth becoming an unwanted side effect.

---

Introduction to Aromatase Inhibitors​

Aromatase inhibitors (AIs) are drugs that block the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).


While primarily used in breast cancer treatment and sometimes in managing gynecomastia, AIs have gained attention for their potential effects on bone growth particularly in increasing:

• Height
• Clavicle length
• Mandibular/maxillary development

 

[Archelaus]

As usual, ask whatever you want, next thread we'll explore the mechanisms behind the effects of aromatize inhibitors, clinical evidence, and potential applications.

(@Mandy? )

 

[Mandy?]

Mirin,good that you mentioned the Var. I wish I could have a good source for a HDAC inhibitor but overall again,high IQ thread and keep going.

 

[Archelaus]

Mirin,good that you mentioned the Var. I wish I could have a good source for a HDAC inhibitor but overall again,high IQ thread and keep going.

I can send u the source androgenic sent me few months back for reta

 

[Mandy?]

I can send u the source androgenic sent me few months back for reta

Damn loox sent you a source? Sure PM me

 

[boxeur]

PTH Analogs: Mechanism of Action​

PTH analogs are engineered to replicate the anabolic effects of endogenous PTH while minimizing undesirable catabolic effects. The two main FDA-approved analogs are:

---

1. Teriparatide (PTH 1-34)​

• Structure: Recombinant fragment containing the first 34 amino acids of PTH (the active binding region).
  • Binds to PTH1 receptors on osteoblasts, activating cAMP/PKA and Wnt/β-catenin pathways.
  • Stimulates osteoblast proliferation and differentiation, increasing bone mineral density (BMD).
• Half life: 1 hour (subcutaneous administration).

---

2. Abaloparatide (PTHrP Analog)​

• Structure: Synthetic analog of parathyroid hormone-related protein (PTHrP), sharing homology with PTH.
  • Selective binding to the RG conformation of PTH1R, favoring bone formation over resorption.
  • Shorter receptor activation time compared to teriparatide, reducing hypercalcemia risk.
• Half-life: 1.7 hours (subcutaneous administration).

---

Clinical Applications​

1. Osteoporosis Treatment​

• Indications:
  
  • Postmenopausal women and men at high fracture risk.
  • Patients unresponsive to bisphosphonates or with severe osteoporosis (T-score < -3.0).
  • Teriparatide increases lumbar spine BMD by 9–13% over 18 months.
  • Abaloparatide shows similar efficacy with a lower hypercalcemia risk.
• Duration: Limited to 24 months (lifetime) due to osteosarcoma risk (observed in rodent studies).

2. Hypoparathyroidism​

• PTH (1-84) (Natpara):
  
  • Full-length recombinant PTH for chronic hypoparathyroidism.
  • Restores calcium homeostasis, reducing reliance on high-dose calcium and vitamin D.
  • Discontinued in 2019 due to manufacturing issues but remains available in some regions.

---

Pharmacokinetics and Administration​

• Route: Subcutaneous injection (daily for teriparatide/abaloparatide).
• Absorption: Rapid, peak concentrations within 30–60 minutes.
• Metabolism: Cleared via renal and hepatic pathways.

---

Adverse Effects and Contraindications​

Common Side Effects​

• Hypercalcemia (more frequent with teriparatide).
• Orthostatic hypotension, dizziness.
• Injection site reactions.

Serious Risks​

• Osteosarcoma: Seen in preclinical studies (no confirmed human cases, but caution advised).
• Hypercalciuria and nephrolithiasis.

Contraindications​

• Paget's disease of bone.
• Prior radiation therapy to bone.
• Pediatric patients (open epiphyses).

---

Practical Application​

• Teriparatide: Administer once per day at 20 micrograms.
• Abaloparatide: Administer once per day at 80 micrograms.

---

HDACI Synergy with Anabolics and Growth Factors​

1. Anavar​

• Increases bone density and height velocity.

2. Trenbolone​

• Very high affinity for the androgen receptor; HDACI will be able to amplify these transcriptional effects and further upregulate AR.

3. Growth Factors + HDACI​

• IGF-1 LR3 / GH: HDACI increase IGF-1R sensitivity, synergizing with GH’s conversion into IGF-1 and other IGF-1 analogues.
• BMP-2/7: Accelerates osteogenesis in targeted areas (e.g., maxilla).

4. Mechanical Loading + HDACI​

• Orthodontics/Orthopedics: HDACI can enhance bone remodeling in response to functional appliances, palatal expanders.
• Manual mechanical force techniques: Remodeling response to applied mechanical force is amplified.

---

Risks​

1. Asymmetry Risk​

• Uneven HDACI + mechanical loading could lead to skewed growth (e.g., mandibular asymmetry).
• Important to apply force evenly and reassess symmetry of growth.

2. Overgrowth Concerns​

• Uncontrolled osteoblast activation might cause excessive bone thickening (e.g., prognathism).
• Not an issue if facial bones are underdeveloped in these areas, but relevant if the focus is on height and frame development, with craniofacial growth becoming an unwanted side effect.

---

Introduction to Aromatase Inhibitors​

Aromatase inhibitors (AIs) are drugs that block the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).


While primarily used in breast cancer treatment and sometimes in managing gynecomastia, AIs have gained attention for their potential effects on bone growth particularly in increasing:

• Height
• Clavicle length
• Mandibular/maxillary development

 

[boxeur]

View attachment 157812

i cant even switch to dark mode vro

 

[BlendedBlade🧿]

Make thread on how do I get bigger dick (not that it’s small but yk)

 

[milkjar]

i cant even switch to dark mode vro

 

[Mandy?]

Make thread on how do I get bigger dick (not that it’s small but yk)

Air pump everyday for 1 minute 30 seconds+cialis. That’s all you need.

 

[BlendedBlade🧿]

Air pump everyday for 1 minute 30 seconds+cialis. That’s all you need.

Can I do throat pump ? Women will do it for me

 

[Archelaus]

View attachment 157812

Over , i can copy paste in black for u wait

 

[Archelaus]

Make thread on how do I get bigger dick (not that it’s small but yk)

I'm lowkey considering making one cuz i doubt the topic would need much research

 

[Archelaus]

PTH Analogs: Mechanism of Action

PTH analogs are engineered to replicate the anabolic effects of endogenous PTH while minimizing undesirable catabolic effects. The two main FDA-approved analogs are:



1. Teriparatide (PTH 1-34)

Structure: Recombinant fragment containing the first 34 amino acids of PTH (the active binding region).
Binds to PTH1 receptors on osteoblasts, activating cAMP/PKA and Wnt/β-catenin pathways.
Stimulates osteoblast proliferation and differentiation, increasing bone mineral density (BMD).
Half life: 1 hour (subcutaneous administration).


2. Abaloparatide (PTHrP Analog)

Structure: Synthetic analog of parathyroid hormone-related protein (PTHrP), sharing homology with PTH.
Selective binding to the RG conformation of PTH1R, favoring bone formation over resorption.
Shorter receptor activation time compared to teriparatide, reducing hypercalcemia risk.
Half-life: 1.7 hours (subcutaneous administration).


Clinical Applications

1. Osteoporosis Treatment

Indications:
Postmenopausal women and men at high fracture risk.
Patients unresponsive to bisphosphonates or with severe osteoporosis (T-score < -3.0).
Teriparatide increases lumbar spine BMD by 9–13% over 18 months.
Abaloparatide shows similar efficacy with a lower hypercalcemia risk.
Duration: Limited to 24 months (lifetime) due to osteosarcoma risk (observed in rodent studies).

2. Hypoparathyroidism

PTH (1-84) (Natpara):
Full-length recombinant PTH for chronic hypoparathyroidism.
Restores calcium homeostasis, reducing reliance on high-dose calcium and vitamin D.
Discontinued in 2019 due to manufacturing issues but remains available in some regions.


Pharmacokinetics and Administration

Route: Subcutaneous injection (daily for teriparatide/abaloparatide).
Absorption: Rapid, peak concentrations within 30–60 minutes.
Metabolism: Cleared via renal and hepatic pathways.


Adverse Effects and Contraindications

Common Side Effects

Hypercalcemia (more frequent with teriparatide).
Orthostatic hypotension, dizziness.
Injection site reactions.

Serious Risks

Osteosarcoma: Seen in preclinical studies (no confirmed human cases, but caution advised).
Hypercalciuria and nephrolithiasis.

Contraindications

Paget's disease of bone.
Prior radiation therapy to bone.
Pediatric patients (open epiphyses).


Practical Application

Teriparatide: Administer once per day at 20 micrograms.
Abaloparatide: Administer once per day at 80 micrograms.


HDACI Synergy with Anabolics and Growth Factors

1. Anavar

Increases bone density and height velocity.

2. Trenbolone

Very high affinity for the androgen receptor; HDACI will be able to amplify these transcriptional effects and further upregulate AR.

3. Growth Factors + HDACI

IGF-1 LR3 / GH: HDACI increase IGF-1R sensitivity, synergizing with GH’s conversion into IGF-1 and other IGF-1 analogues.
BMP-2/7: Accelerates osteogenesis in targeted areas (e.g., maxilla).

4. Mechanical Loading + HDACI

Orthodontics/Orthopedics: HDACI can enhance bone remodeling in response to functional appliances, palatal expanders.
Manual mechanical force techniques: Remodeling response to applied mechanical force is amplified.


Risks

1. Asymmetry Risk

Uneven HDACI + mechanical loading could lead to skewed growth (e.g., mandibular asymmetry).
Important to apply force evenly and reassess symmetry of growth.

2. Overgrowth Concerns

Uncontrolled osteoblast activation might cause excessive bone thickening (e.g., prognathism).
Not an issue if facial bones are underdeveloped in these areas, but relevant if the focus is on height and frame development, with craniofacial growth becoming an unwanted side effect.


Introduct

View attachment 157812

ion to Aromatase Inhibitors

Aromatase inhibitors (AIs) are drugs that block the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).


While primarily used in breast cancer treatment and sometimes in managing gynecomastia, AIs have gained attention for their potential effects on bone growth particularly in increasing:
Height
Clavicle length
Mandibular/maxillary development

 

[boxeur]

PTH Analogs: Mechanism of Action

PTH analogs are engineered to replicate the anabolic effects of endogenous PTH while minimizing undesirable catabolic effects. The two main FDA-approved analogs are:



1. Teriparatide (PTH 1-34)

Structure: Recombinant fragment containing the first 34 amino acids of PTH (the active binding region).
Binds to PTH1 receptors on osteoblasts, activating cAMP/PKA and Wnt/β-catenin pathways.
Stimulates osteoblast proliferation and differentiation, increasing bone mineral density (BMD).
Half life: 1 hour (subcutaneous administration).


2. Abaloparatide (PTHrP Analog)

Structure: Synthetic analog of parathyroid hormone-related protein (PTHrP), sharing homology with PTH.
Selective binding to the RG conformation of PTH1R, favoring bone formation over resorption.
Shorter receptor activation time compared to teriparatide, reducing hypercalcemia risk.
Half-life: 1.7 hours (subcutaneous administration).


Clinical Applications

1. Osteoporosis Treatment

Indications:
Postmenopausal women and men at high fracture risk.
Patients unresponsive to bisphosphonates or with severe osteoporosis (T-score < -3.0).
Teriparatide increases lumbar spine BMD by 9–13% over 18 months.
Abaloparatide shows similar efficacy with a lower hypercalcemia risk.
Duration: Limited to 24 months (lifetime) due to osteosarcoma risk (observed in rodent studies).

2. Hypoparathyroidism

PTH (1-84) (Natpara):
Full-length recombinant PTH for chronic hypoparathyroidism.
Restores calcium homeostasis, reducing reliance on high-dose calcium and vitamin D.
Discontinued in 2019 due to manufacturing issues but remains available in some regions.


Pharmacokinetics and Administration

Route: Subcutaneous injection (daily for teriparatide/abaloparatide).
Absorption: Rapid, peak concentrations within 30–60 minutes.
Metabolism: Cleared via renal and hepatic pathways.


Adverse Effects and Contraindications

Common Side Effects

Hypercalcemia (more frequent with teriparatide).
Orthostatic hypotension, dizziness.
Injection site reactions.

Serious Risks

Osteosarcoma: Seen in preclinical studies (no confirmed human cases, but caution advised).
Hypercalciuria and nephrolithiasis.

Contraindications

Paget's disease of bone.
Prior radiation therapy to bone.
Pediatric patients (open epiphyses).


Practical Application

Teriparatide: Administer once per day at 20 micrograms.
Abaloparatide: Administer once per day at 80 micrograms.


HDACI Synergy with Anabolics and Growth Factors

1. Anavar

Increases bone density and height velocity.

2. Trenbolone

Very high affinity for the androgen receptor; HDACI will be able to amplify these transcriptional effects and further upregulate AR.

3. Growth Factors + HDACI

IGF-1 LR3 / GH: HDACI increase IGF-1R sensitivity, synergizing with GH’s conversion into IGF-1 and other IGF-1 analogues.
BMP-2/7: Accelerates osteogenesis in targeted areas (e.g., maxilla).

4. Mechanical Loading + HDACI

Orthodontics/Orthopedics: HDACI can enhance bone remodeling in response to functional appliances, palatal expanders.
Manual mechanical force techniques: Remodeling response to applied mechanical force is amplified.


Risks

1. Asymmetry Risk

Uneven HDACI + mechanical loading could lead to skewed growth (e.g., mandibular asymmetry).
Important to apply force evenly and reassess symmetry of growth.

2. Overgrowth Concerns

Uncontrolled osteoblast activation might cause excessive bone thickening (e.g., prognathism).
Not an issue if facial bones are underdeveloped in these areas, but relevant if the focus is on height and frame development, with craniofacial growth becoming an unwanted side effect.


Introduct


ion to Aromatase Inhibitors

Aromatase inhibitors (AIs) are drugs that block the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).


While primarily used in breast cancer treatment and sometimes in managing gynecomastia, AIs have gained attention for their potential effects on bone growth particularly in increasing:
Height
Clavicle length
Mandibular/maxillary development

ty

 

[bigdickcel1]

PTH Analogs: Mechanism of Action​

PTH analogs are engineered to replicate the anabolic effects of endogenous PTH while minimizing undesirable catabolic effects. The two main FDA-approved analogs are:

---

1. Teriparatide (PTH 1-34)​

• Structure: Recombinant fragment containing the first 34 amino acids of PTH (the active binding region).
  • Binds to PTH1 receptors on osteoblasts, activating cAMP/PKA and Wnt/β-catenin pathways.
  • Stimulates osteoblast proliferation and differentiation, increasing bone mineral density (BMD).
• Half life: 1 hour (subcutaneous administration).

---

2. Abaloparatide (PTHrP Analog)​

• Structure: Synthetic analog of parathyroid hormone-related protein (PTHrP), sharing homology with PTH.
  • Selective binding to the RG conformation of PTH1R, favoring bone formation over resorption.
  • Shorter receptor activation time compared to teriparatide, reducing hypercalcemia risk.
• Half-life: 1.7 hours (subcutaneous administration).

---

Clinical Applications​

1. Osteoporosis Treatment​

• Indications:
  
  • Postmenopausal women and men at high fracture risk.
  • Patients unresponsive to bisphosphonates or with severe osteoporosis (T-score < -3.0).
  • Teriparatide increases lumbar spine BMD by 9–13% over 18 months.
  • Abaloparatide shows similar efficacy with a lower hypercalcemia risk.
• Duration: Limited to 24 months (lifetime) due to osteosarcoma risk (observed in rodent studies).

2. Hypoparathyroidism​

• PTH (1-84) (Natpara):
  
  • Full-length recombinant PTH for chronic hypoparathyroidism.
  • Restores calcium homeostasis, reducing reliance on high-dose calcium and vitamin D.
  • Discontinued in 2019 due to manufacturing issues but remains available in some regions.

---

Pharmacokinetics and Administration​

• Route: Subcutaneous injection (daily for teriparatide/abaloparatide).
• Absorption: Rapid, peak concentrations within 30–60 minutes.
• Metabolism: Cleared via renal and hepatic pathways.

---

Adverse Effects and Contraindications​

Common Side Effects​

• Hypercalcemia (more frequent with teriparatide).
• Orthostatic hypotension, dizziness.
• Injection site reactions.

Serious Risks​

• Osteosarcoma: Seen in preclinical studies (no confirmed human cases, but caution advised).
• Hypercalciuria and nephrolithiasis.

Contraindications​

• Paget's disease of bone.
• Prior radiation therapy to bone.
• Pediatric patients (open epiphyses).

---

Practical Application​

• Teriparatide: Administer once per day at 20 micrograms.
• Abaloparatide: Administer once per day at 80 micrograms.

---

HDACI Synergy with Anabolics and Growth Factors​

1. Anavar​

• Increases bone density and height velocity.

2. Trenbolone​

• Very high affinity for the androgen receptor; HDACI will be able to amplify these transcriptional effects and further upregulate AR.

3. Growth Factors + HDACI​

• IGF-1 LR3 / GH: HDACI increase IGF-1R sensitivity, synergizing with GH’s conversion into IGF-1 and other IGF-1 analogues.
• BMP-2/7: Accelerates osteogenesis in targeted areas (e.g., maxilla).

4. Mechanical Loading + HDACI​

• Orthodontics/Orthopedics: HDACI can enhance bone remodeling in response to functional appliances, palatal expanders.
• Manual mechanical force techniques: Remodeling response to applied mechanical force is amplified.

---

Risks​

1. Asymmetry Risk​

• Uneven HDACI + mechanical loading could lead to skewed growth (e.g., mandibular asymmetry).
• Important to apply force evenly and reassess symmetry of growth.

2. Overgrowth Concerns​

• Uncontrolled osteoblast activation might cause excessive bone thickening (e.g., prognathism).
• Not an issue if facial bones are underdeveloped in these areas, but relevant if the focus is on height and frame development, with craniofacial growth becoming an unwanted side effect.

---

Introduction to Aromatase Inhibitors​

Aromatase inhibitors (AIs) are drugs that block the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).


While primarily used in breast cancer treatment and sometimes in managing gynecomastia, AIs have gained attention for their potential effects on bone growth particularly in increasing:

• Height
• Clavicle length
• Mandibular/maxillary development

None of this works

 

[Archelaus]

PTH Analogs: Mechanism of Action​

PTH analogs are engineered to replicate the anabolic effects of endogenous PTH while minimizing undesirable catabolic effects. The two main FDA-approved analogs are:

---

1. Teriparatide (PTH 1-34)​

• Structure: Recombinant fragment containing the first 34 amino acids of PTH (the active binding region).
  • Binds to PTH1 receptors on osteoblasts, activating cAMP/PKA and Wnt/β-catenin pathways.
  • Stimulates osteoblast proliferation and differentiation, increasing bone mineral density (BMD).
• Half life: 1 hour (subcutaneous administration).

---

2. Abaloparatide (PTHrP Analog)​

• Structure: Synthetic analog of parathyroid hormone-related protein (PTHrP), sharing homology with PTH.
  • Selective binding to the RG conformation of PTH1R, favoring bone formation over resorption.
  • Shorter receptor activation time compared to teriparatide, reducing hypercalcemia risk.
• Half-life: 1.7 hours (subcutaneous administration).

---

Clinical Applications​

1. Osteoporosis Treatment​

• Indications:
  
  • Postmenopausal women and men at high fracture risk.
  • Patients unresponsive to bisphosphonates or with severe osteoporosis (T-score < -3.0).
  • Teriparatide increases lumbar spine BMD by 9–13% over 18 months.
  • Abaloparatide shows similar efficacy with a lower hypercalcemia risk.
• Duration: Limited to 24 months (lifetime) due to osteosarcoma risk (observed in rodent studies).

2. Hypoparathyroidism​

• PTH (1-84) (Natpara):
  
  • Full-length recombinant PTH for chronic hypoparathyroidism.
  • Restores calcium homeostasis, reducing reliance on high-dose calcium and vitamin D.
  • Discontinued in 2019 due to manufacturing issues but remains available in some regions.

---

Pharmacokinetics and Administration​

• Route: Subcutaneous injection (daily for teriparatide/abaloparatide).
• Absorption: Rapid, peak concentrations within 30–60 minutes.
• Metabolism: Cleared via renal and hepatic pathways.

---

Adverse Effects and Contraindications​

Common Side Effects​

• Hypercalcemia (more frequent with teriparatide).
• Orthostatic hypotension, dizziness.
• Injection site reactions.

Serious Risks​

• Osteosarcoma: Seen in preclinical studies (no confirmed human cases, but caution advised).
• Hypercalciuria and nephrolithiasis.

Contraindications​

• Paget's disease of bone.
• Prior radiation therapy to bone.
• Pediatric patients (open epiphyses).

---

Practical Application​

• Teriparatide: Administer once per day at 20 micrograms.
• Abaloparatide: Administer once per day at 80 micrograms.

---

HDACI Synergy with Anabolics and Growth Factors​

1. Anavar​

• Increases bone density and height velocity.

2. Trenbolone​

• Very high affinity for the androgen receptor; HDACI will be able to amplify these transcriptional effects and further upregulate AR.

3. Growth Factors + HDACI​

• IGF-1 LR3 / GH: HDACI increase IGF-1R sensitivity, synergizing with GH’s conversion into IGF-1 and other IGF-1 analogues.
• BMP-2/7: Accelerates osteogenesis in targeted areas (e.g., maxilla).

4. Mechanical Loading + HDACI​

• Orthodontics/Orthopedics: HDACI can enhance bone remodeling in response to functional appliances, palatal expanders.
• Manual mechanical force techniques: Remodeling response to applied mechanical force is amplified.

---

Risks​

1. Asymmetry Risk​

• Uneven HDACI + mechanical loading could lead to skewed growth (e.g., mandibular asymmetry).
• Important to apply force evenly and reassess symmetry of growth.

2. Overgrowth Concerns​

• Uncontrolled osteoblast activation might cause excessive bone thickening (e.g., prognathism).
• Not an issue if facial bones are underdeveloped in these areas, but relevant if the focus is on height and frame development, with craniofacial growth becoming an unwanted side effect.

---

Introduction to Aromatase Inhibitors​

Aromatase inhibitors (AIs) are drugs that block the conversion of androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).


While primarily used in breast cancer treatment and sometimes in managing gynecomastia, AIs have gained attention for their potential effects on bone growth particularly in increasing:

• Height
• Clavicle length
• Mandibular/maxillary development

@BlendedBlade🧿

 

[vespertine]

my E2 is already barely double digits when I used aromasin I felt god awful